Evidence map›Paper›PMID 29582557›Full record

Trial reportCancer medicine2018

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

Frankie Ann Holmes, Beth A Hellerstedt, John E Pippen, Svetislava J Vukelja, Rufus P Collea, Darren M Kocs, Joanne L Blum, Kristi J McIntyre, Minal A Barve, Barry D Brooks and 4 more

Open access · goldAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Frankie Ann HolmesUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.ORCID 0000-0001-8364-3906
Beth A HellerstedtUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
John E PippenUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Svetislava J VukeljaUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Rufus P ColleaUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Darren M KocsUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Joanne L BlumUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Kristi J McIntyreUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Minal A BarveUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Barry D BrooksUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Cynthia R OsborneUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Yunfei WangUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Lina AsmarUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
Joyce O'ShaughnessyUS Oncology Research, McKesson Specialty Health, The Woodlands, Texas.
McKesson (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5-fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2-positive disease) and to evaluate 5-year disease-free survival (DFS) associated with this preoperative regimen. Chemotherapy included four cycles of FEC100 (5-fluorouracil 500 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineCyclophosphamideDocetaxelEpirubicinFemaleFluorouracilHumansMiddle AgedNeoplasm StagingPreoperative PeriodTime FactorsTrastuzumabCapecitabineCyclophosphamideDocetaxelEpirubicinFluorouracilTrastuzumabBreast cancercapecitabineFECpreoperative chemotherapytrastuzumab

Identifiers

PMID29582557
PMCPMC6010779
OpenAlexW2794979546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.